Author Archive | thomas

Bundesverdienstkreuz for Ugur Sahin and Özlem Türeci

Our heartfelt congratulations: TRON founders Ugur Sahin and Özlem Türeci receive the Order of Merit (Bundesverdienstkreuz) of the German Republic for the short-term development and approval of a vaccine against Covid-19 with their company BioNTech, as announced by the Office of the Federal President. Türeci and Sahin had made a “decisive contribution to the containment

Continue Reading

Iodine-124 PET quantification of organ-specific delivery and expression of NIS-encoding RNA

In this recent study published in European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI), researchers from TRON, JGU Medical Center and BioNTech employed an in vitro transcribed mRNA encoding for sodium iodide symporter (NIS) to efficiently visualize and quantify the biodistribution of NIS RNA-lipoplex nanoparticles targeted to spleen or lung. Tissues expressing the RNA-encoded

Continue Reading

Large-scale analysis of SARS-CoV-2 spike-glycoprotein mutants demonstrates the need for continuous screening of virus isolates

Within the last year, a few infections with the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) quickly turned into the global COVID-19 pandemic infecting and threatening death for millions of people all over the globe. The viral spike protein is responsible for viral binding and entry to host cells and thus mediates infection. Hence, the protein

Continue Reading

TRON researchers contribute to newest BioNTech/Pfizer publication in Nature

Congratulations! TRON researcher Fulvia Vascotto was part of the team around Annette B. Vogel and Ugur Sahin, publishing pre-clinical results in Nature. The study supported the rapid development of BioNTech/Pfizer´s vaccine COMIRNATY (BNT162b2), the now globally deployed mRNA based vaccine against Covid-19. The recently published paper displays immune response data of two vaccine candidates (BNT162b1

Continue Reading

Academy Prize of the State of Rhineland-Palatinate for Ugur Sahin and Özlem Türeci

Dr. Özlem Türeci and Prof. Dr. Ugur Sahin have been awarded the Academy Prize of the State of Rhineland-Palatinate for innovative and forward-looking research for their extraordinary achievements leading to the development of a vaccine against the Corona virus. On behalf of all TRON employees, we warmly congratulate Dr. Özlem Türeci and Professor Ugur Sahin,

Continue Reading

Novel RNA-based therapy for treatment of autoimmune diseases

Loss of immunological self-tolerance followed by attack of self-reactive T cells to target organs plays a major role in the formation of autoimmune diseases such as multiple sclerosis (MS). In a very recent study published in Science, our researchers (in collaboration with Johannes Gutenberg University Medical Center and BioNTech) employed a non-inflammatory RNA vaccine that

Continue Reading

PhD Student Isabell Keil wins poster prize at CLINAM 2020

TRON is thrilled that PhD candidate Isabell Keil has won a prize for her poster at CLINAM 12/2020 (European Foundation for Clinical Nanomedicine’s 12th Annual Meeting)! Isa’s work, featured in the conference’s Basic Nanomedicine category, is to develop nanoparticle‐based mRNA carrier systems for transient immunomodulation of immune cells. Isa’s poster, along with all poster presentations,

Continue Reading

International initiative TESLA identifies parameters for cancer vaccine or cell therapy advancement

Published in Cell: TRON is part of a 36-member alliance led by the Parker Institute and Cancer Research Institute identifying parameters for better vaccine design in the fight against cancer. As part of TESLA (Tumor Neoantigen Selection Alliance), TRON performed advanced computational analysis on samples from melanoma and non-small cell lung cancer to identify characteristics

Continue Reading

Multi-omics characterization of the 4T1 murine mammary gland tumor model

The murine mammary carcinoma cell line 4T1 is a widely used syngeneic tumor model for human breast cancer and specifically triple-negative breast cancer (TNBC). Profiling tumor models is important to translate pre-clinical findings appropriately. The authors aimed to complement the evaluation of 4T1 as adequate breast cancer or even TNBC model. Analysis of the whole-exome

Continue Reading